BEX101 for B-cell non-Hodgkin's lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment called BEX101 for people with certain types of B-cell lymphoma that have come back or not responded to standard treatments. It aims to see if this therapy can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need a confirmed diagnosis of a B-cell non-Hodgkin's lymphoma (like diffuse large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma).
- Your lymphoma must have returned after treatment or not responded to standard therapy.
- You must have at least one measurable tumor that is at least 1.5 cm in size.
- Your tumor must test positive for CD19, a protein on the surface of cancer cells.
- You should be generally healthy, with good organ function (heart, liver, kidneys, and blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
This trial tests an experimental drug called MTM-H-001 given as an injection. It's for people with B-cell lymphoma that has returned or not responded to standard treatments, and it aims to see if the drug can help control the cancer.
This study tests an experimental drug called IMV101 for people with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to other treatments. It aims to see if the drug is safe and if it can shrink tumors.
This trial tests a new drug called SHR-3079 for people with B-cell non-Hodgkin lymphoma whose cancer did not get better or came back after at least one standard treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
Hear when a new Non-Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.